InvestSMART

Raptor Metals Ltd (ASX: RAP) - Announcements

Current share price for RAP : $0.020 0.003 (13.04%)+

ASX company news and announcements for Raptor Metals Ltd (RAP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Raptor Metals Ltd (RAP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Raptor Metals Ltd (RAP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Raptor Metals Ltd (RAP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$8 Appendix 3B and Section 708A Notice 4 Jul 2019 5:04PM $0.180 $0.020 fallen by 88.89%
$8 At-Home Obstructive Sleep Apnoea Study Update 1 Jul 2019 9:29AM $0.195 $0.020 fallen by 89.74%
$8 Extension of CEO and Managing Director's Contract 19 Jun 2019 9:56AM $0.190 $0.020 fallen by 89.47%
$8 Investor Presentation June 2019 13 Jun 2019 9:42AM $0.180 $0.020 fallen by 88.89%
$8 ResApp Receives $1.785 Million R&D Tax Incentive Cash Rebate 12 Jun 2019 9:50AM $0.175 $0.020 fallen by 88.57%
$8 Paediatric Study Published In Peer-Reviewed Journal 6 Jun 2019 10:01AM $0.160 $0.020 fallen by 87.50%
$8 Appendix 3B 5 Jun 2019 5:40PM $0.160 $0.020 fallen by 87.50%
$8 Healthcare Leaders Appointed to Industry Advisory Board 5 Jun 2019 8:36AM $0.175 $0.020 fallen by 88.57%
$8 Market Clarification Announcement 30 May 2019 9:25AM $0.155 $0.020 fallen by 87.10%
$8 Hardware and Wearable Devices to Expand ResApp's Markets 29 May 2019 8:46AM $0.175 $0.020 fallen by 88.57%
$8 Appendix 3B 6 May 2019 6:02PM $0.165 $0.020 fallen by 87.88%
$8 Quarterly Update and Appendix 4C 30 Apr 2019 8:50AM $0.180 $0.020 fallen by 88.89%
$8 Positive Results from Australian Adult Clinical Study 23 Apr 2019 8:48AM $0.125 $0.020 fallen by 84%
$8 ResApp Submits De Novo Application to the FDA 15 Apr 2019 9:38AM $0.120 $0.020 fallen by 83.33%
$8 Update on Australian Adult Study and FDA De Novo Submission 29 Mar 2019 9:31AM $0.072 $0.020 fallen by 72.22%
$8 TechKnow Invest Roadshow Presentation 19 Mar 2019 9:34AM $0.085 $0.020 fallen by 76.47%
$8 Updated Top-line Results from SMARTCOUGH-C-2 Study 18 Mar 2019 9:33AM $0.088 $0.020 fallen by 77.27%
$8 ResApp Receives R&D Advanced Overseas Finding 13 Mar 2019 9:45AM $0.089 $0.020 fallen by 77.53%
$8 Appendix 3B 11 Mar 2019 7:09PM $0.088 $0.020 fallen by 77.27%
$8 Appendix 4D and Half Year Financial Report 28 Feb 2019 2:09PM $0.087 $0.020 fallen by 77.01%
$8 Appendix 3B 25 Feb 2019 8:03PM $0.090 $0.020 fallen by 77.78%
$8 Appendix 3B 11 Feb 2019 5:35PM $0.093 $0.020 fallen by 78.49%
$8 ResApp to Host Investor Q&A Conference Call 4 Feb 2019 9:16AM $0.091 $0.020 fallen by 78.02%
$8 Quarterly Update and Appendix 4C 29 Jan 2019 9:35AM $0.100 $0.020 fallen by 80%
$8 ResApp Submits CE Mark Technical File 2 Jan 2019 9:13AM $0.105 $0.020 fallen by 80.95%

301 - 325 of 573 results

Page 13 of 23

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.